Synthetic Biologics (SYN) Announces Data From Phase 2 Trimesta Trial for RRMS Published by Lead Principal Investigator
Tweet Send to a Friend
Synthetic Biologics (NYSE: SYN) announced today that Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE